Ruling or order

FDA Orders New GLP-1 Risk Warnings Over Vision Loss

Ruling or order from the legal press · reported by 3 publishers

Headline as published by Law360 Product Liability on Nov 9, 2026; collected by the wire Nov 9, 2026, 6:30 PM ET.

Read at Law360 Product Liability

Coverage

  1. Law360 Product Liability Legal press

    FDA Orders New GLP-1 Risk Warnings Over Vision Loss

  2. Legal Scoops Mass tort press

    FDA Orders Vision Loss Warning on Ozempic and Other GLP-1 Drugs

  3. The Legal Examiner Mass tort press

    FDA Orders Vision Loss Warning to Ozempic, GLP-1 Drug Labels

Named in this story

Topics

Explore the named firms, organizations and MDL dockets above. Sources and method

MDL No. 3094

GLP-1 Receptor Agonists

IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation

Transferee judge
Karen S. Marston
Court
Eastern District of Pennsylvania
Actions pending
4,025

Per the JPML pending-dockets report of October 1, 2026.

MDL No. 3163

GLP-1 Vision Loss (NAION)

IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation

Transferee judge
Karen S. Marston
Court
Eastern District of Pennsylvania
Actions pending
247

Per the JPML pending-dockets report of October 1, 2026.